Monograph
C09DA03 - Valsartan and Diuretics |
Propably not porphyrinogenic |
PNP |
Rationale
Valsartan: Not metabolised. Hydrochlorothiazide: South African list: use. French list: autorisé. Australian list: unsafe associated with attacks. Thunell, patient report (n=1): tolerated. Andersson, patient reports (n=10): tolerated. Martindale: Hydrochlorothiazide has been associated with acute attacks of porphyria and is unsafe in porphyric patients. EPI-list: sulfonamides on the unsafe list.
Chemical description
Valsartan: Angiotensin II receptor antagonist. Bioavailability 23 %. Eliminated in unchanged form. Less potent inhibitor of CYP 2C9. Hydrochlortiazide: Tiazide diuretic, sulfonamide congener. Eliminated in urine in unchanged form. Probably no CYP-affinity. Hydrochlortiazide: South African list: use. French list: autorisé. Australian list: unsafe associated with attacks. Thunell, patient report (n=1): tolerated. Andersson, patient reports (n=10): tolerated. Martindale: Hydrochlortiazide has been associated with acute attacks of porphyria and is considred unsafe in porphyric patients. EPI-list: sulfonamides are on the unsafe list.
IPNet drug reports
Uneventful use reported in 3 patients with acute porphyria.
Similar drugs
Tradenames
This list comprises raw data collected from different countries.
In some cases, a more comprehensive list of available drug packages is included.
Consequently, very similar terms may therefore appear multiple times.
Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
© NAPOS 2025